Axa S.A. Prothena Corp Public LTD CO Transaction History

Axa S.A.

$33.1 Billion
Q2 2024

A detailed history of Axa S.A. transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Axa S.A. holds 120,719 shares of PRTA stock, worth $2.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

120,719

Previous 120,650 0.06%

Holding current value

$2.42 Million

Previous $2.99 Million 16.63%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$19.54 - $26.15 $1,348 - $1,804	69 Added 0.06%	120,719 $2.49 Million
Q1 2024 May 15, 2024	BUY	$24.75 - $40.66 $816 - $1,341	33 Added 0.03%	120,650 $2.99 Million
Q4 2023 Jul 16, 2024	SELL	$32.31 - $52.32 $1,066 - $1,726	-33 Reduced 0.03%	120,617 $4.38 Million
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $248,916 - $403,073	7,704 Added 6.82%	120,617 $4.38 Million
Q3 2023 Nov 14, 2023	SELL	$47.3 - $70.6 $19,061 - $28,451	-403 Reduced 0.36%	112,913 $5.45 Million
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $4.55 Million - $7.42 Million	94,364 Added 497.91%	113,316 $7.74 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $42,273 - $52,443	-900 Reduced 4.53%	18,952 $918,000
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $1.69 Million - $2.1 Million	-32,373 Reduced 61.99%	19,852 $1.2 Million
Q3 2022 Feb 14, 2023	BUY	$25.16 - $60.63 $651,644 - $1.57 Million	25,900 Added 98.39%	52,225 $3.17 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $651,644 - $1.57 Million	25,900 Added 98.39%	52,225 $3.17 Million
Q2 2022 Feb 14, 2023	SELL	$22.73 - $39.98 $199,455 - $350,824	-8,775 Reduced 25.0%	26,325 $714,000
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $199,455 - $350,824	-8,775 Reduced 25.0%	26,325 $715,000
Q1 2022 Feb 14, 2023	SELL	$30.27 - $49.22 $518,373 - $842,892	-17,125 Reduced 32.79%	35,100 $1.28 Million
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $1.06 Million - $1.73 Million	35,100 New	35,100 $1.28 Million
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $3.84 Million - $6.28 Million	-79,660 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$21.63 - $57.65 $1.91 Million - $5.1 Million	-88,389 Reduced 52.6%	79,660 $4.1 Million
Q1 2021 May 14, 2021	SELL	$11.0 - $28.24 $85,800 - $220,272	-7,800 Reduced 4.44%	168,049 $4.22 Million
Q2 2020 Aug 14, 2020	SELL	$9.56 - $12.51 $58,889 - $77,061	-6,160 Reduced 3.38%	175,849 $1.84 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $15.77 $266,162 - $556,681	35,300 Added 24.06%	182,009 $1.95 Million
Q3 2019 Nov 14, 2019	BUY	$6.89 - $10.45 $298,240 - $452,338	43,286 Added 41.85%	146,709 $1.15 Million
Q2 2019 Aug 13, 2019	BUY	$8.85 - $12.49 $672,272 - $948,777	75,963 Added 276.63%	103,423 $1.09 Million
Q2 2018 Aug 13, 2018	SELL	$10.99 - $44.21 $1.27 Million - $5.1 Million	-115,421 Reduced 80.78%	27,460 $400,000
Q1 2018 May 14, 2018	SELL	$27.95 - $45.04 $40,164 - $64,722	-1,437 Reduced 1.0%	142,881 $5.25 Million
Q4 2017 Feb 13, 2018	SELL	$35.44 - $63.76 $5,209 - $9,372	-147 Reduced 0.1%	144,318 $5.41 Million
Q3 2017 Nov 13, 2017	BUY	$53.83 - $67.75 $7.78 Million - $9.79 Million	144,465	144,465 $9.36 Million

Others Institutions Holding PRTA

# of Institutions

182

Shares Held

42.7M

Call Options Held

77.7K

Put Options Held

92.7K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $940M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account